Market Insights
What are CINV Existing and Pipeline Drugs?
Vomiting and nausea are two of the most common side effects which are associated with cancer chemotherapy and are regarded as chemotherapy-induced nausea and vomiting (CINV). Chemotherapy has helped millions of people worldwide in their battle against cancer, which helps in destroying cancer cells and their growth. Although, while eliminating the cancer cells, this therapy sometimes destroys the healthy noncancerous cells, which can lead to unwanted side effects. The introduction of two new drugs, namely rolapitant and SUSTOL (extended generic granisetron) for treating CINV has gained popularity in the past few years.
The CINV Existing and Pipeline Drugs Market is estimated to grow from USD 1.9 billion in 2020 to USD 2.7 billion by 2026 at a healthy CAGR of 5.9% during the forecast period.
|
CINV Existing and Pipeline Drugs Market- Research Scope
|
|
Base Year of Study
|
2020
|
|
Trend Period
|
2015-2019
|
|
Forecast Period
|
2021-2026
|
|
Market Size in 2020
|
US$ 1.9 billion
|
|
Market Size in 2026
|
US$ 2.7 billion
|
|
Market Growth (2021-2026)
|
5.9% CAGR
|
Figure: CINV Existing and Pipeline Drugs Market Size, 2020-2026(USD Billion)
Wish to get a free sample. Register Here
Market Drivers
Increasing incidences of different types of cancer is a key factor propelling the global CINV existing and pipeline drugs market growth during the review period. Also, technological developments for the introduction of new drugs further augment product usage. A substantial rise in the research & development activities for cancer coupled with a growing focus on the innovation of new drugs boosts the industry growth. Furthermore, the launch of new drugs, as well as the strong development of the healthcare sector, offer lucrative opportunities to the market players. However, limited awareness among consumers regarding the availability of new drugs and treatments is likely to hamper the market expansion in the near future.
Covid-19 Impact Analysis
The outbreak of COVID-19 moderately impacted the CINV existing and pipeline drugs industry as the pandemic adversely affected the international trade activities, supply chains, and manufacturing activities across the globe. There were postponement and delays of oncology appointments due to stringent social distancing norms and fear among patients, which slowed the chemotherapy among cancer patients, which is likely to negatively affect the product consumption, amid the pandemic.
Segments' Analysis
End-Use Trends
Based on end-use, the CINV existing and pipeline drugs market has been divided into hospitals, specialty clinics, diagnostic centers therapeutics, hospital pharmacies, and drugstores. The hospitals' segment held a significant market share in 2020. Hospitals are the common setting where cancer patients are treated. Hospitals are well-equipped with medical infrastructure and facilities with qualified oncology specialists, thus boosting the segment growth.
Regional Trends
By region, the North American CINV Existing and Pipeline Drugs market accounted for the largest share in 2020 and is expected to grow at a significant CAGR during the review period. The CINV Existing and Pipeline Drugs market growth can be ascribed to a large presence of leading biotechnology companies, easy approval of CINV drugs, highly developed healthcare & research infrastructure, strong focus on drug discovery, and rising cancer cases in the region.
The Asia-Pacific CINV Existing and Pipeline Drugs market is expected to grow at the highest CAGR during the review on account of the growth of the major end-use industries. This growth is mainly ascribed to the presence of many clinical research organizations & biopharmaceutical companies in China, Japan, and India for drug discovery and development. Also, sedentary lifestyle, high population growth, surging cancer cases, and improving healthcare infrastructure further bolster the regional market growth during the review period.
Critical Questions Answered in the Report
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global CINV existing and pipeline drugs market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026. Following are the critical questions answered in the report.
- What are the key trends in the CINV existing and pipeline drugs market?
- How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
- What is the impact of COVID-19 on CINV existing and pipeline drugs market?
- What are the key strategies adopted by the major vendors to lead in the CINV existing and pipeline drugs market?
- What is the market share of the top vendors?
Get the full scope of the report. Register Here
Key Players
Key players operating in the CINV Existing and Pipeline Drugs Market are-
- GlaxoSmithKline (UK)
- Helsinn (Switzerland)
- Heron Therapeutics (US)
- Merck (Germany)
- Tesaro (US)
- Eastman (US)
- Lonza (Switzerland)
- CHEMIDEA CHEMICALS (China)
- Teva pharmaceutical (Israel)
- Baxter Healthcare (US)
Target Audience
The target audience of CINV Existing and Pipeline Drugs Market includes-
- CINV Existing and Pipeline Drugs Vendors
- CINV Existing and Pipeline Drugs Manufacturers
- CINV Existing and Pipeline Drugs Distributors
- Organizations
- Government Bodies.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
